Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis

摘要

Background:Coronavirus disease 2019(COVID-19)has killed over 2.5 million people worldwide,but effective care and therapy have yet to be discovered.We conducted this analysis to better understand tocilizumab treatment for COVID-19 patients.Main text:We searched major databases for manuscripts reporting the effects of tocilizumab on COVID-19 patients.A total of 25 publications were analyzed with Revman 5.3 and R for the meta-analysis.Significant better clinical outcomes were found in the tocilizumab treatment group when compared to the standard care group[odds ratio(OR)=0.70,95%confidential interval(CI):0.54-0.90,0.007].Tocilizumab treatment showed a stronger correlation with good prognosis among COVID-19 patients that needed mechanical ventilation(OR=0.59,95%CI:0.37-0.93,P=0.02).